Performance Evaluation of the Dreem 3 System for Sleep Assessment in Patients With Insomnia

Not Applicable

Completed

• Conditions: Insomnia
• Interventions: Device: Dreem 3 System vs PSG

• Registration Number: NCT05438017
• Lead Sponsor: Dreem

Brief Summary

The objective of the clinical investigation is to assess the performance of the Dreem 3 System for sleep assessment compared to a FDA-cleared PSG assessment and human sleep expert scoring in a population experiencing insomnia symptoms.

Detailed Description

Subjects enrolled in the study will come to the sleep laboratory around 8 pm. Their involvement in the protocol will only require them to be equipped by the technician with Dreem 3 in addition to the PSG reference system. This involves the technician placing all the PSG electrodes on the subject's head as per normal practice, and then positioning the Dreem 3 headband so that both devices can operate simultaneously. The subject will be allowed to go to his/her room and do quiet activities (reading, film watching, chatting) prior to sleeping. At the end of the night, the technician will remove the Dreem 3 headband and the PSG.

A technical quality control will be performed on the collected data in accordance with the standard operating procedures, as defined in the study protocol. Recordings that do not meet the quality control criteria will be excluded from further analysis.

Subjects will receive the PSG report at the end of the study.

Study Timeline

• Study Start: 2022-04-21
• Study First Submitted: 2022-06-24
• Study First Submitted QC: 2022-06-28
• Study First Posted: 2022-06-29
• Status Verified: 2022-07
• Primary Completion: 2022-07-08
• Study Completion: 2022-07-08
• Last Update Submitted: 2022-07-28
• Last Update Posted: 2022-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

• Subjects must be ≥ 22 and ≤ 70 years old inclusive.
• Able to read, understand and sign an informed consent form.
• Subjects with stable disease or/and taking stable medications for at least 2 months can be included under Principal Investigator or Sub-Investigator discretion
• Self-reported insomnia symptoms (by means of a questionnaire completed by the participant before their visit to the sleep lab) as defined by International Classification of Sleep Disorders, third edition (ICSD-3), confirmed by a clinician.

Exclusion Criteria

• Female subjects who are pregnant, or breastfeeding.

• Subject under 22 and above 70 years old inclusive.

• Not able to read, understand and sign an informed consent form

• Subjects with BMI ≥ 40

• Taking medications that induce somnolence or wakefulness, or that can interfere with sleep recording:

  • If the subject is taking OTC medications that can induce somnolence or wakefulness, he/she must not take it the day of the measurement.
  • Prescription only drugs that induce somnolence or wakefulness must be stopped one week before, as PI or Sub-I discretion and/or review with subject's physician.

• Subjects previously diagnosed with Obstructive Sleep Apnea (OSA), REM Sleep Disorder, Narcolepsy, Hypersomnia, or significant difficulty breathing due to underlying condition(s), or subjects diagnosed with Central Nervous System (CNS) disease.

• Subjects that suffer from an unstable disease

• Any incidental finding on the Polysomnography reference system, happening during the study recording, that interferes with eligibility (probable moderate/severe undiagnosed OSA)

• Subjects who may experience fitting difficulties with the headband, including people with head circumference < 53cm, or a hairstyle impeding the sensor placement (tight braids, hair extension, dreadlocks...) as determined by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dreem + PSG	Dreem 3 System vs PSG	-

Primary Outcome Measures

Name	Time	Method
Performance of the automatic sleep stage scoring of the Dreem 3 System compared to the consensus of 3 independent certified sleep scorers realized on the polysomnography signal.	Day 1

Secondary Outcome Measures

Name	Time	Method
Total time spent in N3 sleep stage	Day 1	Total time (in minutes) the subject spends in AASM N3 sleep stage as automatically determined by the Dreem 3 System compared to the N3 time determined by the consensus of 3 certified sleep scorers' scoring of the subject's PSG record from the same night.
Total time spent in REM sleep stage	Day 1	Total time (in minutes) the subject spends in AASM REM sleep stage as automatically determined by the Dreem 3 System compared to the REM time determined by the consensus of 3 certified sleep scorers' scoring of the subject's PSG record from the same night.
LPS (Latency to Persistent Sleep)	Day 1	Latency to Persistent Sleep (in minutes) as automatically determined by the Dreem 3 System compared to the latency to persistent sleep determined by the consensus of 3 certified sleep scorers' scoring of the subject's PSG record from the same night.
Total time spent in N1 sleep stage	Day 1	Total time (in minutes) the subject spends in AASM N1 sleep stage as automatically determined by the Dreem 3 System compared to the N1 time determined by the consensus of 3 certified sleep scorers' scoring of the subject's PSG record from the same night.
Respiratory Rate	Day 1	Respiratory rate for each 30 second epoch (in cycles per minute) computed by the accelerometer of the Dreem device compared to the respiratory rate computed by the PSG sensor.
TST (Total Sleep Time)	Day 1	Total time (in minutes) the subject spends asleep (TST) as automatically determined by the Dreem 3 System compared to the TST determined by the consensus of 3 certified sleep scorers' scoring of the subject's PSG record from the same night.
SE (Sleep Efficiency)	Day 1	Sleep efficiency (%) as automatically determined by the Dreem 3 System compared to the sleep efficiency determined by the consensus of 3 certified sleep scorers' scoring of the subject's PSG record from the same night.
Total time spent in N2 sleep stage	Day 1	Total time (in minutes) the subject spends in AASM N2 sleep stage as automatically determined by the Dreem 3 System compared to the N2 time determined by the consensus of 3 certified sleep scorers' scoring of the subject's PSG record from the same night.
SOL (Sleep Onset Latency)	Day 1	Sleep Onset Latency (in minutes) as automatically determined by the Dreem 3 System compared to the sleep onset latency determined by the consensus of 3 certified sleep scorers's scoring of the subject's PSG record from the same night.
WASO (Wake After Sleep Onset)	Day 1	Total time (in minutes) the subject spends awake from sleep onset to final epoch of sleep (WASO) as automatically determined by the Dreem 3 System compared to the WASO determined by the consensus of 3 certified sleep scorers' scoring of the subject's PSG record from the same night.

Trial Locations

Locations (2)

Biotrial Inc; 🇺🇸 Newark, New Jersey, United States

Biotrial Rennes; 🇫🇷 Rennes, France